Partners with Ascensia Diabetes Care for expansion in ASEAN markets
BeatO, a leading Indian digital health platform for chronic condition management, announced its foray into the Southeast Asian market with the launch of its operations in Singapore. The company has partnered with Ascensia Diabetes Care, to expand its presence in the Asean market and offer comprehensive digital diabetes care and self-management to Singapore.
The expansion comes in line with the company’s objectives of catering to markets with a high incidence of diabetes, as Singapore has 10.5 per cent prevalence of diabetes compared to the world average of 8.8 per cent. The company plans to build new networks in international geographies while going deeper into existing markets and forming a stronger national network of partners.
Through the partnership with Ascensia, users can integrate BeatO’s app ecosystem with their Ascensia monitoring devices. BeatO will be investing significantly in business development and improving the product and technology for the Singaporean market. The BeatO app in Singapore has been customised to lifestyle, usage patterns and culture of the regional market.
The smart connected chronic care management ecosystem is powered by AI, providing actionable insights to manage diabetes, hypertension and offering an entire ecosystem to help users manage their chronic condition. BeatO combines cost-effective IoT hardware –– with the BeatO app to support end-to-end management for users.
Commenting on the expansion, Gautam Chopra, Co-founder & CEO, BeatO, said, “We are excited to launch BeatO in Singapore and offer customised comprehensive digital diabetes care and self-management solutions to people with diabetes in the region. In terms of both business growth and patient outcomes, we have seen an overwhelming response during the past year. Engagement rates of users have soared by 50 per cent, increasing the time spent on the platform by 25-30 per cent. Given the high prevalence of diabetes across regions, ASEAN is an important market for us. We believe the Singapore market holds tremendous potential and look forward to creating a meaningful impact on the local healthcare system. Through this expansion, we also intend to double our user base by the end of FY21.”
